

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

PanOxyl 10 Wash 10% w/w Lotion

PanOxyl Wash 10%

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Benzoyl peroxide 10.0% w/w

For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Lotion for cutaneous use.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

PanOxyl Wash 10% is indicated for the treatment of acne vulgaris.

4.2 Posology and method of administration

Adults and adolescents

The patient should wet the skin areas to be treated, apply gently massaging for one or two minutes, rinse thoroughly and pat dry. Use once a day.

If excessive dryness or peeling occurs frequency of application should be reduced or temporarily interrupted as per physician instruction or patient tolerability.

Maximum lesion reduction may be expected after approximately eight to twelve weeks of drug use. Continued use is normally required to maintain a clinical response.

Elderly patients

There are no specific recommendations for use in the elderly.

Paediatric Population

Safety and effectiveness of topical PanOxyl in children under the age of 12 has not been established.

4.3 Contraindications

Patients with a known hypersensitivity to any of the ingredients should not use the product.

4.4 Special warnings and precautions for use

Avoid contact with the eyes, eyelids, mouth, lips and other mucous membranes. Contact with broken skin should be avoided. Care should be taken when applying the product to the neck and other sensitive areas.

During the first weeks of treatment, a sudden increase in peeling and reddening will occur in most patients and will normally subside in a day or two if treatment is temporarily discontinued.

Patients should be advised that excessive application will not improve efficacy, but may increase the risk of skin irritation.

Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy may occur, which sometimes may be severe, especially with the use of peeling, desquamating, or abrasive agents.

If severe local irritancy occurs (e.g. severe erythema, severe dryness and itching, severe stinging/burning sensation), PanOxyl should be discontinued.

PanOxyl may cause increased sensitivity to sunlight, sunlamps should not be used and deliberate or prolonged exposure to sunlight should be avoided or minimised. When exposure to strong sunlight cannot be avoided, patients should be advised to use a sunscreen product and wear protective clothing.

The product may bleach hair and coloured or dyed fabrics.

Avoid contact with hair, fabrics, furniture or carpeting.

4.5 Interaction with other medicinal products and other forms of interaction

Concomitant application of PanOxyl with tretinoin, isotretinoin, and tazarotene should be avoided since it may reduce their efficacy and increase irritation. If combination treatment is required, the products should be applied at different times of the day (e.g., one in the morning and the other in the evening.)

Using topical PanOxyl at the same time as topical sulfonamide-containing products may cause skin and facial hair to temporarily change colour (yellow/orange).

4.6 Fertility, Pregnancy and lactation

Fertility

There are no data on the effect of topical benzoyl peroxide on fertility.

Pregnancy

There are limited data on the use of topical benzoyl peroxide in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see Section 5.3). No effects during pregnancy are anticipated since systemic exposure to benzoyl peroxide is very limited.

However, benzoyl peroxide should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus.

Lactation

Percutaneous absorption of benzoyl peroxide is very limited; however, it is not known whether benzoyl peroxide is excreted in human milk after topical application.

Topical benzoyl peroxide should be used during lactation only if the expected benefit justifies the potential risk to the infant.

If used during lactation, benzoyl peroxide should not be applied to the breast area to avoid accidental ingestion by the infant.

4.7 Effects on ability to drive and use machines

Not Relevant

4.8 Undesirable effects

Adverse reactions are classified by System Organ Class. Adverse reactions that occurred either during clinical studies or that were spontaneously reported are presented below:

Frequencies were defined as follows:

Very common $\geq 1/10$

Common $\geq 1/100$ to $< 1/10$

Uncommon $\geq 1/1000$ to $< 1/100$

Rare $\geq 1/10000$ to $< 1/1000$

Very rare $< 1/10000$

Not known* (cannot be estimated from the available data).

Immune System Disorders

Not known: Allergic reactions, including application site hypersensitivity and anaphylaxis

Skin and Subcutaneous Tissue Disorders

Very Common: Peeling, application site erythema

Common: Dryness, pruritus and contact sensitisation reactions

Uncommon: Burning sensation

Not known: Application site rash

General Disorders and Administration Site Conditions

Not known: Application site discoloration and application site reactions such as irritation and pain

4.9 Overdose

Symptoms and signs

Topically applied benzoyl peroxide is not generally absorbed in sufficient amounts to produce systemic effects.

Excessive application may result in severe irritation. In this event, discontinue use and wait until the skin has recovered.

Treatment

Cold compresses can provide relief from irritation due to excessive application.

Accidental ingestion of topical benzoyl peroxide should be managed clinically or as recommended by the National Poisons Centre, where available.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Benzoyl peroxide

ATC code: D10AE01

Mechanism of action

Benzoyl peroxide is a highly lipophilic oxidizing agent with bacteriocidal and keratolytic effects.

Pharmacodynamic effects

The effectiveness of benzoyl peroxide in the treatment of acne vulgaris is primarily attributable to its antibacterial activity, especially with respect to *Propionibacterium acnes*. The antibacterial activity of benzoyl peroxide is due to the release of active or free-radical oxygen capable of oxidising bacterial proteins. Benzoyl peroxide is also believed to be effective in the treatment of acne on account of its anti-inflammatory and mild keratolytic properties.

5.2 Pharmacokinetic properties

Absorption/Distribution/Metabolism

Benzoyl peroxide is absorbed by the skin where it is metabolised to benzoic acid. Following topical application, less than 5% of the dose enters systemic circulation as benzoic acid.

Elimination

Benzoyl peroxide is excreted as benzoic acid in the urine.

5.3 Preclinical safety data

Carcinogenesis/mutagenesis

Both the carcinogenicity and photocarcinogenicity of benzoyl peroxide have been extensively assessed in both mice and hamsters, by various routes of administration, in studies ranging from 42 to 100 weeks in duration. The overall conclusion is that benzoyl peroxide is considered to be generally recognized as a neither carcinogenic nor photocarcinogenic and safe in topical acne products at a concentration of 2.5% to 10%.

The genotoxicity of benzoyl peroxide was extensively assessed *in vitro* and *in vivo*. While in a few *in vitro* studies benzoyl peroxide showed weak mutagenicity, the overall genotoxicity profile did not indicate significant biological relevance.

Reproductive Toxicology

Fertility and Pregnancy

In a combined repeat- dose and reproduction/development toxicity study, benzoyl peroxide (250, 500 or 1,000 mg/kg/day) was administered orally to male rats for 29 days and female rats for 41-51 days. There were no treatment-related changes observed in the mating period, mating rate, conception rate, delivery rate, birth rate, pregnancy period, luteinization number, implantation number and the rate of losing embryos and fetuses after implantation. In pups, body weight was significantly decreased in the high-dose group. The no-observed-adverse-effect-level (NOAEL) for reproductive toxicities was considered to be 500 mg/kg/day.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Magnesium aluminium silicate

Citric acid monohydrate

Sodium alkyl aryl polyether sulphonate

Sodium dihexyl sulphosuccinate
Sodium lauryl sulphoacetate
Hypromellose
Polyoxyethylene lauryl ether
Imidurea
Purified water

6.2 Incompatibilities

None

6.3 Shelf life

18 months

6.4 Special precautions for storage

Store below 25°C.

6.5 Nature and contents of container

Flip top polyethylene bottle containing 150 ml.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

There are no special instructions for use or handling of PanOxyl Wash 10%.

7 MARKETING AUTHORISATION HOLDER

Avianta Pharma Limited,
Unit H, Ashbourne Drive,
Leamington Spa,
England,
CV31 3SS,
United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)

PL 49226/0018

**9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION**

20/10/2005

10 DATE OF REVISION OF THE TEXT

06/11/2025